Compare ICMB & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICMB | CPIX |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.8M | 34.1M |
| IPO Year | N/A | 2009 |
| Metric | ICMB | CPIX |
|---|---|---|
| Price | $2.82 | $2.57 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.8K | ★ 92.6K |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | ★ 18.70% | N/A |
| EPS Growth | ★ 31.51 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | $17,931,778.00 | ★ $41,278,349.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.75 | N/A |
| P/E Ratio | $7.25 | ★ N/A |
| Revenue Growth | N/A | ★ 12.21 |
| 52 Week Low | $2.46 | $1.85 |
| 52 Week High | $3.47 | $7.25 |
| Indicator | ICMB | CPIX |
|---|---|---|
| Relative Strength Index (RSI) | 47.40 | 56.08 |
| Support Level | $2.74 | $2.11 |
| Resistance Level | $2.90 | $2.73 |
| Average True Range (ATR) | 0.09 | 0.23 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 21.87 | 72.60 |
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.